Mereo BioPharma (MREO) Receivables - Other (2017 - 2023)

Mereo BioPharma (MREO) has reported Receivables - Other for 7 consecutive years, with $2.0 million the latest figure, recorded in Q4 2023.

• Quarterly Receivables - Other rose 118.18% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (up 118.18% YoY) and the FY2023 annual result came in at $2.0 million, changed N/A from the prior year.
• Receivables - Other rose to $2.0 million in Q4 2023 per MREO's latest filing, from $893771.4 in the prior quarter.
• Over the last five years, Receivables - Other for MREO reached as high as $2.5 million in Q2 2019 and fell as low as $735434.6 in Q4 2019.
• A 5-year average of $1.5 million and a median of $1.4 million in 2021 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other plunged 36.85% — and 2023, when it surged 118.18%.
• Year by year, Receivables - Other stood at $735434.6 in 2019, then climbed by 15.99% to $853011.3 in 2020, then jumped by 63.09% to $1.4 million in 2021, then plunged by 35.75% to $893771.4 in 2022, then jumped by 118.18% to $2.0 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.0 million, $893771.4, and $1.3 million for Q4 2023, Q4 2022, and Q2 2022 respectively.